Neurocrine Biosciences Aktie
137,30
EUR
+0,90
EUR
+0,66
%
158,31
USD
-0,64
USD
-0,40
%
Neurocrine Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Neurocrine Biosciences Aktie Analyse
| 14.10.05 | Neurocrine Biosciences overweight | Prudential Financial | |
| 08.09.05 | Neurocrine Biosciences outperform | Piper Jaffray | |
| 04.08.05 | Neurocrine Biosciences outperform | Piper Jaffray | |
| 25.07.05 | Neurocrine Biosciences outperform | Piper Jaffray | |
| 21.07.05 | Neurocrine Biosciences buy | UBS | |
| 20.07.05 | Neurocrine Biosciences Buy | UBS | |
| 18.07.05 | Neurocrine Biosciences outperform | Thomas Weisel Partners | |
| 18.07.05 | Neurocrine Biosciences Outperform | Thomas Weisel Partners | |
|
Werbung
|
|||
| 14.02.05 | Neurocrine Biosciences Overweight | Lehman Brothers | |
Werbung
Werbung